Akums launches Ripasudil + Timolol combination for glaucoma treatment

The new combination therapy offers a dual mechanism of action for superior intraocular pressure control

Novo Nordisk strikes $1bn deal for Lexicon’s oral obesity drug

Lexicon Pharmaceuticals announces exclusive license agreement with Novo Nordisk for LX9851

Sanofi & Regeneron’s Dupixent receives Japanese marketing approval to treat patients with COPD

Dupixent (dupilumab) approved as the first-ever biologic medicine in Japan for patients with Chronic Obstructive Pulmonary Disease (COPD)

Alembic Pharma and Amlan International partner to advance poultry health in India

Alembic Pharmaceuticals Ltd. and Amlan International sign exclusive strategic commercial agreement to make poultry health innovations accessible to Indian farmers and integrators

Cadila launches Cadilose for constipation and hepatic encephalopathy

Glenmark launches nutrition program to fight malnutrition in Philippines

This program, titled "Food Supplementation and Capacity Building Support for Improved Nutrition in Malinao, Aklan," aligns with the country’s national health

Merck inks $200 million deal for Hengrui's midstage heart disease drug

Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region

Marksans Pharma’s manufacturing facility at Verna, Goa approved by Australian TG

The products will be manufactured in Goa India and marketed & distributed in Australian markets

Lupin bags EcoVadis Silver Medal for sustainability excellence

Over the last two years, Lupin has showcased exceptional improvement in its EcoVadis scoring

Glenmark receives ANDA approval for Olopatadine Hydrochloride ophthalmic solution USP, 0.2%

Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC), will be distributed in the US by Glenmark Therapeutics, USA.